On Thursday, Shares of WisdomTree Investments, Inc. (NASDAQ:WETF), gained 8.98% to $19.54.
WisdomTree Investments stated net income of $24.2 million for the second quarter of 2015 or $0.18 per share on a fully diluted basis. This compares to $10.6 million in the second quarter of 2014 and $12.1 million in the first quarter of 2015.
WisdomTree CEO and President Jonathan Steinberg said, “Our innovative ETF platform attracted $6.6 billion in inflows in the second quarter and more than $20 billion in the first half of the year, making WisdomTree one of the fastest-growing companies within the ETF and broader asset administration industry in 2015 to date. We also delivered industry-leading operating margins and record financial results, demonstrating the increasing scale and strength of our business model.”
WisdomTree Investments, Inc., through its auxiliaries, operates as an exchange-traded funds (ETFs) sponsor and asset manager. It offers ETFs in equities, currency, fixed income, and alternatives asset classes.
Shares of Celgene Corporation (NASDAQ:CELG), inclined 3.20% to $123.04, during its last trading session.
Celgene Corporation, declared it has closed its acquisition of Receptos, Inc. Receptos stockholders received $232.00 per share in cash, for a total of about $7.2 billion, net of cash attained. Because of the completion of the merger, the common stock of Receptos is no longer listed for trading on the NASDAQ Global Market or any other exchange and trading ceased at the close of the markets on Thursday, August 27, 2015.
Receptos stockholders who hold shares through a bank or broker will not have to take any action to have their shares converted into cash, since these conversions will be handled by the bank or broker. Stockholders who hold stock certificates can surrender their certificates for $232.00 per share in cash, without interest and less any applicable withholding taxes, through the paying agent for the merger, American Stock Transfer & Trust Company, LLC.
The acquisition of Receptos significantly enhances Celgene’s Inflammation & Immunology (I&I) portfolio, further diversifies the Company’s predictable revenue starting in 2019, and builds upon Celgene’s growing expertise in inflammatory bowel disease (IBD). The transaction adds Ozanimod, a novel, potential best in class, oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator (S1P) to Celgene’s deep and diverse pipeline of potential disease-altering medicines and investigational compounds.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally.
At the end of Thursday’s trade, Shares of Boeing Co (NYSE:BA), gained 1.96% to $131.87.
Boeing, declared the completion of the firm configuration milestone for the 777-9, the first member of the 777X family to be developed.
The Boeing 777X team reached this noteworthy design milestone after working closely with airline customers and key suppliers to optimize the configuration of the new airplane.
The 777X family comprises the 777-8 and the 777-9 – both designed to respond to market needs and customer preferences. The 777-8 and 777-9 provide noteworthy range, payload and fuel burn advantages contrast to the A350.
The Boeing Company, together with its auxiliaries, designs, develops, manufactures, sells, services, and supports commercial jetliners, military aircraft, satellites, missile defense, human space flight, and launch systems and services worldwide. The company operates in five segments: Commercial Airplanes, Boeing Military Aircraft, Network & Space Systems, Global Services & Support, and Boeing Capital.
Finally, MasTec, Inc. (NYSE:MTZ), ended its last trade with 5.37% gain, and closed at $15.51.
MasTec, declared 2015-second quarter financial results and updated its guidance for the balance of the year.
Second quarter 2015 revenue reduced 3.7% to $1.07 billion from $1.1 billion in the preceding year quarter. The quarterly revenue change was primarily composed of revenue declines in the Electrical Transmission and Communications segments, partially offset by revenue enhances in the Oil & Gas and Power Generation & Industrial segments. Second quarter 2015 net loss from ongoing operations was $3.8 million, or $0.05 per diluted share, contrast to net income from ongoing operations of $33.7 million, or $0.39 per diluted share, for the second quarter of 2014. Second quarter 2015 results comprise about $0.14 per diluted share for non-operating and non-core charges not comprised of in preceding year results, composed primarily of WesTower acquisition integration costs, Audit Committee investigation related costs and the nonrecurring impact of an income tax law change in Alberta, Canada.
Second quarter 2015 adjusted net income from ongoing operations, a non-GAAP measure, was $8.1 million contrast to $36.4 million in 2014. Second quarter 2015 ongoing operations adjusted diluted earnings per share, a non-GAAP measure, was $0.10, contrast to $0.42 last year. Second quarter 2015 ongoing operations adjusted EBITDA, also a non-GAAP measure, was $71.0 million contrast to $108.4 million in 2014.
MasTec, Inc., an infrastructure construction company, provides engineering, building, installation, maintenance, and upgrade services for communications, energy, and utility infrastructure in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
